Lollar P
Department of Medicine, Emory University, Atlanta, GA 30322, USA.
Thromb Haemost. 1997 Jul;78(1):647-51.
Recombinant hybrid human/porcine factor VIII molecules have been used to map a major determinant of the epitope recognized by human anti-factor VIII A2 domain inhibitory antibodies to a region bounded by human fVIII residues Arg484-Ile508. This approach is being used to characterize the C2 domain inhibitor epitope. The process of creating hybrid human/porcine factor VIII molecules to map inhibitor epitopes produces procoagulantly active fVIII with reduced reactivity with clinically significant factor VIII inhibitors. This suggests that it may be possible to develop of a hybrid human/porcine factor VIII that is useful in the management of hemophilia A and acquired hemophilia.
重组人/猪杂交因子VIII分子已被用于将人抗因子VIII A2结构域抑制性抗体识别的表位的主要决定簇定位到由人fVIII残基Arg484 - Ile508界定的区域。该方法正用于表征C2结构域抑制剂表位。创建人/猪杂交因子VIII分子以定位抑制剂表位的过程产生了促凝活性fVIII，其与临床上重要的因子VIII抑制剂的反应性降低。这表明有可能开发出一种对A型血友病和获得性血友病治疗有用的人/猪杂交因子VIII。
